Arpeggio Biosciences raises $3.2M in seed round

BOULDER — Arpeggio Biosciences Inc. raised $3.2 million in its seed round this week as part of its drug testing 

The six-employee company, which lists its address at the same building as the University of Colorado Boulder’s BioFrontiers Institute, had an additional $2 million worth of investor interest in the round, according to a company statement.

The seed round has not been reported to the U.S. Securities and Exchange Commission as of Wednesday morning.

Arpeggio is developing a machine-learning system that analyzes how the cells of a patient reacts to a drug during clinical trials. That data can be used to more clearly determine how a drug produces both intended outcomes and unforeseen side effects.

The company plans to use the seed funding for ongoing development of a test to measure drug effects on a patient’s RNA.

Arpeggio raised just under $2.1 million in two pre-seed stage funding rounds last year, according to SEC records.

CEO Joey Azofeifa was named in Forbes Magazine’s 2020 Thirty Under Thirty in health care last month.

on Facebook on LinkedIn